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Abstract: Postprandial hypotension (PPH), a fall in systolic blood pressure (SBP) within 2 h of a
meal, may detrimentally affect gait parameters and increase the falls risk in older people. We aimed
to determine the effects of postprandial SBP on heart rate (HR), gait speed, and stride length,
double-support time and swing time variability in older subjects with and without PPH. Twenty-nine
subjects were studied on three days: glucose (“G”), water and walk (“WW”), glucose and walk
(“GW”). Subjects consumed a glucose drink on “G” and “GW” and water on “WW”. The “G” day
determined which subjects had PPH. On “WW” and “GW” gait was analyzed. Sixteen subjects
demonstrated PPH. In this group, there were significant changes in gait speed (p = 0.040) on “WW”
and double-support time variability (p = 0.027) on “GW”. The area under the curve for the change in
gait parameters from baseline was not significant on any study day. Among subjects without PPH,
SBP increased on “WW” (p < 0.005) and all gait parameters remained unchanged on all study days.
These findings suggest that by changing gait parameters, PPH may contribute to an increased falls
risk in the older person with PPH.
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1. Introduction
Falls are common in older people, with a prevalence of 30% and 50% among community
dwelling individuals and older people living in residential care facilities, respectively [1–3]. A major
consequence of falls is fractures, which pose a considerable public health issue due to the association
with detrimental physical and psychological morbidity [4,5], as well as significant health care costs [6].
Falls risk factors are typically multifactorial [7] and include postprandial hypotension (PPH) and gait
impairments [5,8].
PPH is a condition that is defined as a 20 mmHg reduction in systolic blood pressure (SBP) or a
decline in SBP to less than 90 mmHg from a pre-ingestion SBP of greater than 100 mmHg, occurring
within 2 h of meal commencement [9,10]. There is a strong association between PPH and falls in older
people. PPH is present in 25% of older inpatients with a history of falls [11], 50% of older persons
with unexplained falls occurring within 2 h of a meal [9] and in 58% of older patients seen in a falls
outpatient clinic [12].
There is a strong association between gait impairment and falls, such that when the former is
evident, the risk of falls is increased [5,7,13,14]. In a review of 12 studies evaluating falls risk factors
among older people, gait impairment was identified as the second largest contributory cause for
falls [5]. Moreover, a systematic review and meta-analysis of 74 studies investigating risk factors
for falls among community-dwelling older people found that gait impairment ranked as the second
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strongest falls risk factor [14]. Specific gait parameters that have been robustly associated with falls are
a decrease in gait speed and an increase in the variability of stride length, double-support time and
swing time [15–17].
Previous studies have determined that a relationship exists between: (a) falls and PPH [9,11,12,18];
and (b) falls and gait impairment [5,7,13,14]. However, it is uncertain if the decline in SBP evident in
people with PPH has an effect on gait parameters which may then predispose the older person to falls.
Hence, the aim of this study was to determine if a postprandial decline in SBP affects gait speed, stride




Twenty-nine older subjects (18 female (mean age 77.1 ˘ 5.4 years), 11 male (mean age
74.7 ˘ 3.9 years)) with and without PPH were recruited from geriatrician clinics at The Queen Elizabeth
Hospital, from lists of research subjects that had previously participated in research studies or via
community events related to the Healthy Ageing Program undertaken by the Adelaide Geriatrics
Training and Research with Aged Care (G-TRAC) Centre. Recruitment occurred through a number of
methods in order to minimize selection bias, and consistent criteria was used to recruit and enroll all
subjects into the study. Subjects aged 65 years and above were included in the study with the exception
of those who had a history of significant cardiovascular disease (myocardial infarction less than three
months earlier, clinical coronary artery disease or symptomatic congestive heart failure), significant
respiratory disease, renal impairment, epilepsy, dysphagia, chronic alcohol abuse or excessive cigarette
smoking (more than 10 cigarettes a day). Subjects withheld usual medication on the morning of the
study days.
This research study was approved by the Human Research Ethics Committee of The Queen
Elizabeth Hospital/Lyell McEwin Hospital/Modbury Hospital, Adelaide, Australia (protocol
number 2011011; 1 November 2011). Each subject provided written, informed consent before the
commencement of the first study day. All experiments were carried out in accordance with the
Declaration of Helsinki.
2.2. Experimental Design
Each subject was studied on three randomized study days, separated by a minimum of 72 h.
To minimize bias, an online randomization program [19] was used. On each study day, subjects
underwent an overnight fast (10 h for solids and 6 h for liquids) and in the preceding 24 h refrained
from alcohol and caffeine containing beverages, and smoking for 12 h.
The subjects attended the Basil Hetzel Institute at The Queen Elizabeth Hospital at 0830 h on
each day and upon arrival were seated comfortably in a chair. An automated blood pressure cuff
was placed around the right arm and following a 10 min rest period, at t = 0 min, subjects ingested
a study drink. On two of the study days, (glucose (“G”) and glucose and walk (“GW”)), the drink
consisted of 50 g glucose (glucose monohydrate, Fluka Analytical, Sigma-Aldrich Pty Ltd., Castle Hill,
NSW, Australia) dissolved in water (total volume of the drink 200 mL). On the other study day, the
drink consisted of 200 mL of water alone (“WW”). The purpose of the “G” day was to establish which
subjects had PPH so that the subjects could be grouped; it has been well established that ingestion of
a glucose drink induces a rapid fall in SBP, the magnitude of which fulfills the definition of PPH [9],
i.e., a 20 mmHg fall in SBP after glucose ingestion [9]. On one day, cardiovascular autonomic nerve
function and orthostatic blood pressure were evaluated before the commencement of the study [20].
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2.3. Assessment of Subject Health Status
Before the commencement of the first study day, subjects were interviewed by a medical doctor
using a standardized questionnaire consisting of questions relating to demographic variables, medical
history, medication use, history of falls and fear of falls. This information was obtained via telephone,
with the use of a questionnaire sent by mail and by directly interviewing the subject in person on
the first study day. Global assessment of health status was assessed by calculating the Charlson
Comorbidity Index (CCI), a measure of comorbidity which predicts the one-year mortality rate for a
patient by taking into account both the number and severity of 19 pre-defined comorbid conditions [21].
Each condition is assigned a score of 1, 2, 3 or 6, depending on the mortality risk associated with the
condition. The scores are summed and a total score is derived. The one-year mortality rates for the
different scores are: “0”: 12%; “1–2”: 26%; “3–4”: 52%; and “greater than or equal to “5””: 85% [21].
Fear of falls was assessed using the Falls Efficacy Scale International, a widely accepted tool for
assessing concern about falling [22], which has been validated in an Australian population [23]. It is a
self-reporting questionnaire, providing information on the level of concern about falls for a range of
16 activities of daily living scored on a four-point scale anchored at one end by 1 = not at all concerned
and the other end by 4 = very concerned. A score of 23 and above indicates a high concern about
falling [23].
2.4. Blood Pressure and Heart Rate Measurements
SBP and heart rate (HR) were measured using an automated oscillometric blood pressure monitor
(Spacelabs Ultralite 24 hour ABP, JLM Accutek Health Care, Homebush, NSW, Australia). On all study
days, “baseline” SBP and HR (t = 0 min) were calculated as the mean of measurements taken at t = ´9,
´6, and ´3 min before ingestion of the drink. SBP and HR were measured every 6 min between
t = 0–60 min and then every 15 min between t = 60–120 min.
2.5. Gait Parameters Acquisition and Analysis
Gait parameters were measured using the GAITRite® walkway system (CIR Systems Inc.,
Franklin, NJ, USA). This system consisted of a 6 m portable walkway with a series of sensor pads
activated by mechanical pressure [24]. Data from the sensors were collected by a series of on-board
processors and transferred and stored on a computer. Previous studies have demonstrated that the
GAITRite® measures gait parameters with strong concurrent validity and test-retest reliability in older
people [24–27]. Gait speed and variability in stride length, double-support time and swing time were
recorded at each subject’s self-selected walking speed, i.e., at a pace deemed comfortable by each
individual subject. These parameters were selected as they have been identified as the most clinically
relevant in terms of association with falls in older people [13,15–17]; a decline in gait speed [13,15,16,19]
and increased variability in stride length, double-support time and swing time have been identified as
risk factors for future falls [17]. In this study, gait speed was derived by dividing the distance walked
by the ambulation time [28]. Stride length was determined by the anterior-posterior distance between
the heels of two consecutive footprints of the same foot [29,30]. Double-support time was assessed as
the time that both feet were on the ground simultaneously [29,30]. Swing time was measured as the
time elapsed between the last contact of the current footfall to the initial contact of the next footfall of
the same foot [29,30]. Variability, which refers to the intra-individual stride-to-stride fluctuations in
gait characteristics [29], was calculated by dividing the standard deviation by the mean of the relevant
gait parameter and multiplying this by 100 ((standard deviation/mean) ˆ 100) [29].
Gait was analyzed on the “WW” and “GW” days only. At t = ´20 min, subjects undertook two
practice walks to familiarize themselves with the protocol and GAITRite®, followed by two test walks.
Subsequent gait analysis every 30 min between t = 30–120 min involved two test walks only (i.e., no
practice walks). Gait measurements were calculated as the mean of the two walks [31]. To ensure a
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consistent walking pace, subjects commenced and completed walking approximately 2 m before and
after the walkway [31,32], i.e., total walking distance was 10 m.
2.6. Cardiovascular Autonomic Function
Autonomic nerve function was assessed using standardized cardiovascular reflex tests [33,34].
Parasympathetic function was determined by the variation (R-R interval) of HR during deep breathing
and response to standing (30:15 ratio). Sympathetic function was assessed by the fall in SBP in
response to standing. Each of the test results was scored according to age-adjusted predefined criteria
as 0 = normal, 1 = borderline and 2 = abnormal for a total maximum score of 6. A score > 3 was
considered to indicate autonomic dysfunction [33,34].
2.7. Orthostatic Blood Pressure
Orthostatic hypotension was determined by measuring SBP in the supine position and then
after standing for one and three min. Orthostatic hypotension was diagnosed as a decline in SBP of
20 mmHg or more and/or a decline in diastolic blood pressure of 10 mmHg or more between the
supine and standing positions, evident on at least one of the time points [35].
2.8. Statistical Analysis
Power calculations from preliminary data from the first five subjects with PPH enrolled in this
study determined that to detect a difference of 10 cm/s in gait speed, 16 subjects with PPH were
required to provide an 80% power, at the 0.05 significance level. A value of 10 cm/s was chosen as
this has been demonstrated to be clinically relevant [36]. SBP, HR, gait speed, stride length variability,
double-support time variability and swing time variability were analyzed as changes from baseline.
One-way analysis of variance was used to analyze the effects of time on these variables.
The maximum changes in SBP, HR, gait speed, stride length variability, double-support time
variability and swing time variability were defined as the greatest mean changes from baseline in each
subject at any given time point for each study day, and is reported where a significant change from
baseline is demonstrated. The area under the curve (AUC) between t = 0–120 min was calculated using
the trapezoidal rule and analyzed by paired t-test to evaluate a “treatment” effect for SBP, HR, gait
speed, stride length variability, double-support time variability and swing time variability.
Subjects’ characteristics were summarized using means and standard deviations, or frequencies
and percentages, as appropriate. Comparisons between the characteristics of subject groups were
performed using the chi-squared test and independent-samples t-test. All analyses were performed
using SPSS Version 20 (SPSS Inc., Chicago, IL, USA). Data are presented as means ˘ standard deviation
(SD). A p value < 0.05 was considered statistically significant in all analyses. Analyses were performed
with the assistance of a professional biostatistician.
3. Results
3.1. Subject Characteristics
All recruited subjects completed the research study, which was well tolerated with no adverse
effects reported. Sixteen of the 29 subjects demonstrated PPH, defined as a decline of 20 mmHg in SBP
occurring within 2 h of consuming the study drink [9,10] on the “G” day (Table 1).
Subjects’ characteristics are summarized in Table 2. When compared with subjects without PPH,
those subjects with PPH had a significantly higher (p = 0.006) CCI (i.e., indicating that this group had
more co-morbidities), and significantly more subjects with hypertension (p = 0.034) and increased
antihypertensive use (p = 0.017). Furthermore, amongst this group, four had orthostatic hypotension
and of these, two also had definite autonomic dysfunction. In contrast, among subjects without PPH,
only two had orthostatic hypotension and none had autonomic dysfunction. There were no significant
differences between the two groups of subjects for all other variables in the assessment of health status.
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1 145 120 25 105 1 127 113 14 60
2 169 141 28 30 2 140 129 11 36
3 145 102 43 105 3 119 107 12 90
4 136 113 23 105 4 126 123 3 18
5 153 133 20 18 5 130 119 11 42
6 134 107 27 24 6 125 113 12 18
7 166 143 23 75 7 150 134 16 36
8 158 138 20 105 8 132 118 14 60
9 144 114 30 18 9 124 113 11 30
10 173 126 47 60 10 151 135 16 18
11 145 120 25 120 11 154 151 3 18
12 132 109 23 105 12 157 143 14 54
13 133 113 20 42 13 103 95 8 30
14 136 116 20 18
15 167 134 33 48
16 154 134 20 36
Mean ˘ SD 26.69 ˘ 8.43 54.0 ˘ 36.0 11.0 ˘ 3.0 42.0 ˘ 10.0
Abbreviations: SBP, systolic blood pressure; PPH, postprandial hypotension; max, maximum; SD, standard deviation.
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Table 2. Subjects’ characteristics.
Characteristic Subjects withPPH (n = 16)
Subjects no
PPH (n = 13) p Value
Age, years (mean ˘ SD) 76.5 ˘ 4.1 75.8 ˘ 6.0 0.742
Sex (n/%)
0.441female 5 (31) 6 (46)
male 11 (69) 7 (54)
History of falls in preceding 12 months (n/%) 3 (19) 0 0.099
Falls Efficacy Scale International score (mean ˘ SD) 16.8 ˘ 4.8 19.5 ˘ 6.3 0.230
Orthostatic hypotension (n/%) 4 (25) 2 (15) 0.627
Autonomic dysfunction (n/%) 3 (19) 0 0.099
Charlson Comorbidity Index (mean ˘ SD) 2.0 ˘ 0.9 1.2 ˘ 0.4 0.006
Hypertension (n/%) 10 (63) 3 (23) 0.034
Heart disease (n/%) 3 (19) 1 (8) 0.390
Diabetes mellitus (n/%) 1 (6) 0 0.842
Hypothyroidism (n/%) 2 (13) 1 (8) 0.672
Antihypertensives (n/%) 12 (75) 4 (31) 0.017
ACEI 2 (13) 0
ARB 7 (44) 1 (8)
Beta Blockers 1 (6) 1 (8)
CCB 4 (25) 3 (23)
Diuretics 1 (6) 1 (8)
Abbreviations: PPH, postprandial hypotension; SD, standard deviation; ACEI, angiotensin converting enzyme
inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
3.2. Baseline Gait Parameters
Table 3 summarizes baseline gait speed, and variability in stride length, double-support time and
swing time. There were no significant differences between the two groups of subjects for these baseline
parameters.
Table 3. Baseline gait parameters.
Characteristic Subjects with PPH (n = 16) Subjects No PPH (n = 13) p Value
Gait speed “WW” day 112.9 ˘ 21.9 116.8 ˘ 27.0 0.674
Gait speed “GW” day 113.8 ˘ 22.0 114.4 ˘ 24.0 0.945
Stride length variability “WW” day 3.5 ˘ 1.4 2.6 ˘ 1.3 0.085
Stride length variability “GW” day 3.4 ˘ 1.4 2.6 ˘ 1.6 0.163
Double-support time variability “WW” day 14.1 ˘ 10.9 17.9 ˘ 17.9 0.484
Double-support time variability “GW” day 13.9 ˘ 12.1 17.0 ˘ 24.0 0.649
Swing time variability “WW” day 9.4 ˘ 11.7 11.4 ˘ 16.1 0.702
Swing time variability “GW” day 6.0 ˘ 6.3 15.0 ˘ 21.1 0.157
Abbreviations: PPH, postprandial hypotension; SD, standard deviation; SBP, systolic blood pressure; WW,
water and walk; GW, glucose and walk.
3.3. Systolic Blood Pressure
3.3.1. Subjects with PPH
There was a significant fall in SBP over time between t = 0–120 min on the “G” day (p < 0.005)
and no signficant change on the “GW” (p = 0.397) or “WW” (p = 0.067) days. The mean maximum
fall, and time of fall, in SBP on the “G” day were 26.69 ˘ 8.43 mm Hg at 54.0 ˘ 36.0 min (Table 1).
Between t = 0–120 min there was a significant treatment effect for the AUC for the change in SBP from
baseline between the study days (p < 0.005). During this time, compared to the “G” day, SBP was
significantly greater during the “GW” day (95% CI = ´1741–´271, p = 0.007) and “WW” day (95%
CI = ´2469–´1259, p < 0.005) (Figure 1a). At t = 120 min, SBP was significantly less than baseline on the
“G” day (p = 0.001) and there was no difference on the “GW” (p = 0.446) or the “WW” (p = 0.080) days.
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Figure 1. Mean change () in systolic blood pressure (SBP) on “G” (), “WW” () and “GW” () 
days in subjects: (a) with postprandial hypotension (PPH); and (b) without PPH. Data are mean ± 
standard deviation (SD) represented by vertical bars. * p < 0.005 and ** p = 0.010 for the area under the 
curve (AUC) for the change in SBP from baseline between the study days. 
3.3.2. Subjects without PPH 
There were no significant changes in SBP over time between t = 0–120 min on the “G” (p = 0.108) 
or “GW” (p = 0.683) days. There was a significant increase in SBP over time between t = 0–120 min on 
the “WW” day (p < 0.005). The mean maximum increase, and time of increase, in SBP on the “WW” 
day were 6.62 ± 13.51 mmHg at 42 ± 29 min. Between t = 0–120 min there was a significant treatment 
effect for the AUC for the change in SBP from baseline between the study days (p = 0.010). During 
this time, SBP was significantly greater during the “WW” day (95% CI = −951–−157, p = 0.007) than 
the “G” day but not during the “GW” day (95% CI = −562–−951, p = 1.000) (Figure 1b). At t = 120 min, 
SBP was not different from baseline on the “G” (p = 0.679), “WW” (p = 0.410) or “GW” (p = 0.510) days. 
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“GW” (p = 0.271) or “WW” (p = 0.465) days. Between t = 0–120 min, there was no significant treatment 
effect for the AUC for the change in HR from baseline between the study days (95% CI = −218–419, p 
= 0.220) (Figure 2a). At t = 120 min, HR was not significantly different than baseline on the “G” (p = 
0.117), “GW” (p = 0.307) or “WW” (p = 0.197) days. 
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deviation (SD) represented by vertical bars. * p < 0.005 and ** p = 0.010 for the area under the curve
(AUC) for the change in SBP from baseline between the study days.
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3.4. Heart Rate
3.4.1. Subjects with PPH
There were no significant changes in HR over time between t = 0–120 min on the “G” (p = 0.667),
“GW” (p = 0.271) or “WW” (p = 0.465) days. Between t = 0–120 min, there was no significant treatment
effect for the AUC for the change in HR from baseline between the study days (95% CI = ´218–419,
p = 0.220) (Figure 2a). At t = 120 min, HR was not significantly different than baseline on the “G”
(p = 0.117), “GW” (p = 0.307) or “WW” (p = 0.197) days.
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3.4.2. Subjects without PPH 
There were no significant changes in HR over time between t = 0–120 min on the “G” (p = 0.567), 
“GW” (p = 0.905) or “WW” (p = 0.755) days. Between t = 0–120 min, there was no significant treatment 
effect for the AUC for the change in HR from baseline between the study days (95% CI = 258–332, p = 
0.116) (Figure 2b). At t = 120 min, HR was not significantly different than baseline on the “G” (p = 
0.646), “GW” (p = 0.527) or “WW” (p = 1.000) days. 
3.5. Gait Speed 
3.5.1. Subjects with PPH 
There was no signficant change in gait speed on the “GW” day (p = 0.071). However, there was 
a significant change in gait speed over time between t = 0–120 min on the “WW” day (p = 0.040). The 
mean maximum change, and time of change, in gait speed on the “WW” day were −4.34 ± 10.01 cm/s 
at 60.0 ± 33.0 min. Between t = 0–120 min, there was no significant treatment effect for the AUC for 
the change in gait speed from baseline between the study days (95% CI = −289–930, p = 0.280) (Figure 
3a). At t = 120 min, gait speed was not different from baseline on the “WW” day (p = 0.126). 
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Figure 3. Mean change () in gait speed on “WW” () and “GW” () days in subjects: (a) with 
postprandial hypotension (PPH); and (b) without postprandial PPH. Data are mean ± standard 
deviation (SD) represented by vertical bars. * p = 0.040 for the change in gait speed over time on the 
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3.4.2. Subjects without PPH
There were no significant changes in HR over time between t = 0–120 min on the “G” (p = 0.567),
“GW” (p = 0.905) or “WW” (p = 0.755) days. Between t = 0–120 min, there was no significant treatment
effect for the AUC for the change in HR from baseline between the study days (95% CI = 258–332,
p = 0.116) (Figure 2b). At t = 120 min, HR was not significantly different than baseline on the “G”
(p = 0.646), “GW” (p = 0.527) or “WW” (p = 1.000) days.
3.5. Gait Speed
3.5.1. Subjects with PPH
There was no signficant change in gait speed on the “GW” day (p = 0.071). However, there
was a significant change in gait speed over time between t = 0–120 min on the “WW” day
(p = 0.040). The mean maximum change, and time of change, in gait speed on the “WW” day were
´4.34 ˘ 10.01 cm/s at 60.0 ˘ 33.0 min. Between t = 0–120 min, there was no significant treatment effect
for the AUC for the change in gait speed from baseline between the study days (95% CI = ´289–930,
p = 0.280) (Figure 3a). At t = 120 min, gait speed was not different from baseline on the “WW” day
(p = 0.126).
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3.5.2. Subjects without PPH 
There were no significant changes in gait speed over time between t = 0–120 min on the “WW” 
(p = 0.225) or “GW” (p = 0.308) days. Between t = 0–120 min, there was no significant treatment effect 
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for the AUC for the change in gait speed from baseline between the study days (95% CI = ´289–930,
p = 0.280) (Figure 3b). At t = 120 min, gait speed was not different from baseline on the “WW” (p = 0.169)
or “GW” days (p = 0.973).
3.6. Stride Length Variability
3.6.1. Subjects with PPH
There were no significant changes in stride length variability over time between t = 0–120 min
on the “GW” (p = 0.344) or “WW” (p = 0.402) days. Between t = 0–120 min, there was no significant
treatment effect for the AUC for the change in stride length variability from baseline between the “WW”
and “GW” days (95% CI = ´132–69, p = 0.513) (Figure 4a). At t = 120 min, stride length variability was
not different from baseline on the “WW” (p = 0.156) or “GW” (p = 0.825) days.
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and time of change, in double-support time variability on the “GW” day was 10.83 ± 25.03 cm/s at 
60.0 ± 28.0 min. Between t = 0–120 min, there was no significant treatment effect for the AUC for the 
change in double-support time variability from baseline between the “WW” and “GW” days (95% CI 
= −666–813, p = 0.835) (Figure 5a). At t = 120 min, double-support time variability was not different 
from baseline on the “WW” (p = 0.830) or “GW” (p = 0.853) days. 
3.7.2. Subjects without PPH 
There were no significant changes in double-support time variability over time between t = 0–
120 min on the “WW” (p = 0.257) or “GW” (p = 0.222) days. Between t = 0–120 min, there was no 
significant treatment effect for the AUC for the change in double-support time variability from 
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ef ect for the AUC for the change in stride length variability from baseline between th “WW”
and “GW” days (95% CI = ´132–69, p = 0.513) (Figure 4b). At t = 120 min, stride length variability was
not different from baseline on the “WW” (p = 0.789) or “GW” (p = 0.599) days.
3.7. Double-Support Time Variability
3.7.1. Subjects with PPH
There was a significant change (p = 0.027) in double-support time variability over time between
t = 0–120 min on the “GW” day, but not on the “WW” day (p = 0.339). The mean maximum change,
and time of change, in double-support time variability on the “GW” day was 10.83 ˘ 25.03 cm/s at
60.0 ˘ 28.0 min. Between t = 0–120 min, there was no significant treatment effect for the AUC for the
change in double-support time variability from baseline between the “WW” and “GW” days (95%
CI = ´666–813, p = 0.835) (Figure 5a). At t = 120 min, double-support time variability was not different
from baseline on the “WW” (p = 0.830) or “GW” (p = 0.853) days.
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3.8.2. Subjects without PPH 
There were no significant changes in swing time variability between t = 0–120 min on the “WW” 
(p = 0.363) or “GW” (p = 0.594) days. Between t = 0–120 min, there was no significant treatment effect 
for the AUC for the change in swing time variability from baseline between the “WW” and “GW” 
days (95% CI = −318–1323, p = 0.207) (Figure 6b). At t = 120 min, swing time variability was not 
different from baseline on the “WW” (p = 0.995) or “GW” (p = 0.188) days. 
4. Discussion 
Figure 5. ean change (4) in double-support time variability (DSTV) on “W ” (#) and “GW” ( ) days
in subjects: (a) with postprandial hypotension (PPH); and (b) without PPH. Data are mean ˘ standard
deviation (SD) represented by vertical bars. * p = 0.027 for the change in DSTV over time on the
“GW” day.
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3.7.2. Subjects without PPH
There were no significant changes in double-support time variability over time between
t = 0–120 min on the “WW” (p = 0.257) or “GW” (p = 0.222) days. Between t = 0–120 min, there
was no significant treatment effect for the AUC for the change in double-support time variability from
baseline between the “WW” and “GW” days (95% CI =´648–1337, p = 0.464) (Figure 5b). At t = 120 min,
double-support time variability was not different from baseline on the “WW” (p = 0.154) or “GW”
(p = 0.900) days.
3.8. Swing Time Variability
3.8.1. Subjects with PPH
There were no significant changes in swing time variability over time between t = 0–120 min
on the “WW” (p = 0.798) or “GW” (p = 0.342) days. Between t = 0–120 min, there was no significant
treatment effect for the AUC for the change in swing time variability from baseline between the “WW”
and “GW” days (95% CI = ´1331–193, p = 0.133) (Figure 6a). At t = 120 min, swing time variability
was not different from baseline on the “WW” (p = 0.556) or “GW” (p = 0.186) days.
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4. Discussion
This is the first study to evaluate the effects of postprandial SBP on gait parameters known to be
associated with increased risk of falls [15–17], in older individuals with and without PPH. The results of
this study indicate that in older subjects with PPH, there is a significant change in: (1) double-support
time variability following glucose ingestion; and (2) gait speed following water ingestion.
Regarding SBP, as expected on the glucose only day (“G”), there was a significant decline in
SBP among subjects with PPH. However, there was no significant change in SBP on the glucose day
(“GW”), due to the effect of intermittent walking, which has been shown to attenuate the hypotensive
effect of glucose in older subjects with PPH [37].
Gait involves the interplay between motor, sensory, visual, vestibular, cerebellar, cognitive,
psychological and musculoskeletal systems [38–40]. It has been suggested that in hypotensive states,
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the accompanying reduction in cerebral perfusion pressure may cause gait unsteadiness, potentially
by affecting the vestibular, cerebellar and musculoskeletal systems [41]. Furthermore, there is evidence
that hypotension is associated with poorer cognitive function, in particular executive function [42],
which involves the ability to plan, sequence tasks and make judgments [43]. This may be the possible
mechanism by which PPH resulted in a change in double-support time variability. An increase
in double-support time variability is associated with an increased falls risk in older people [17],
particularly recurrent falls [17]. Therefore, this suggests an avenue by which PPH may contribute to an
increased falls risk in the older person.
A reduction in gait speed is shown to be associated with an increased falls risk in older
people [13,15,16,19]. Specifically, gait speed is an independent predictor of fall related femoral neck
fractures [15]. Apart from the association with falls, a reduction in gait speed has also been associated
with increased frailty in older people [44]. Keeping in mind that there are multiple systems influencing
gait [41], the finding that there was a significant change in gait speed following water ingestion among
subjects with PPH suggests that there are other mechanisms apart from hypotension that contribute to
worsening of gait parameters, such as frailty. PPH could be considered more common among older
people who are frail given that the prevalence of PPH is higher among older people in residential
care [18,45] compared to older people residing at home [46,47]. Therefore, although frailty was not
directly measured in this study, it may be possible that the older subjects with PPH were also more
frail. Another factor that may have contributed to a change in gait speed among older subjects with
PPH post water ingestion may be the possible effects of fasting. On the glucose day (“GW”) when
compared with the water day (“WW”), fasting was not as prolonged as at t = 0 min subjects ingested
a glucose drink before walking, whereas on the water day subjects consumed only water. To date,
there have been no studies exploring the relationship between gait speed in the fasted, compared to a
non-fasted, state particularly in older people who may be more vulnerable.
The lack of HR increase noted in this study is consistent with our previous finding [37] and
those of others [47]. We have previously discussed [37] additional mechanisms at play that may be
contributing to the development of PPH including abnormalities in the baroreceptor function [48], the
age-related decline in b-adrenergic responsiveness to sympathetic activation [49,50] and concomitant
usage of HR lowering medication such as beta blockers and calcium channel blockers [49,50].
While the strength of this study is that it specifically investigated the effects on gait parameters
of glucose and water ingestion in older people with and without PPH, it is important to point out its
limitations. Although powered to detect the primary outcome, it should be noted that the sample
size was relatively small. As discussed, low-intensity intermittent walking has been suggested as a
possible intervention to reduce the postprandial fall in SBP evident in people with PPH [37]. Therefore,
the walking protocol may have limited the potential influence on gait parameters and future research
should consider this in its design. For example, the maximum change in gait speed was noted at 60 min
post drink ingestion and so it might be beneficial to undertake an investigation to study the effects
of glucose ingestion on gait speed in subjects with PPH at this specific time point only. In addition,
it remains unknown whether prolonged sitting has an impact on gait measurements and this will
also need to be considered in future study design. As discussed, cognitive impairment and vestibular
dysfunction are common in the older population and may influence gait [38,39]. Both were not
measured in this study and, therefore, may have potentially affected the study outcomes. The presence
of vestibular dysfunction could contribute to a decline in gait speed [51] and a decline in cognitive
function is associated with an increased variability in gait parameters [52]. However, as the study
recruited subjects that had previously participated in research studies or attended community events,
it was anticipated that significant cognitive impairment would not be present in this study group.
An assessment of muscle strength or exercise tolerance was not undertaken and may have influenced
gait speed. Older people who exercise have been shown to have an increased gait speed [53,54]
while reduced lower extremity strength is associated with a lower gait speed [55]. Lastly, this study
highlights the challenge of undertaking gait research. In view that gait involves the coordination
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between multiple systems, gait assessments should include a comprehensive evaluation of factors that
could influence gait. The CCI does not capture musckuloskeletal related conditions which could affect
gait such as arthirits, or sensory deficits which also influence gait. Perhaps measuring frailty which
is increasingly recognized as an important aspect of assessing the health status in older people [56]
would have been more appropriate. The most robust gait parameter associated with frailty is a decline
in gait speed [57–59] while an increase in stride length variability [57] has also been demonstrated to
be associated with frailty.
5. Conclusions
This study establishes for the first time that in older people with PPH, glucose ingestion results in
a change in double-support time variability, a parameter known to be associated with increased falls
risk in older people. The effect of PPH on other gait parameters may have been mitigated due to the
effect of intermittent walking which is known to diminish the postprandial hypotensive response.
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PPH postprandial hypotension
SBP systolic blood pressure
HR heart rate
G glucose
WW water and walk
GW glucose and walk
AUC area under the curve
G-TRAC Adelaide Geriatrics Training and Research with Aged Care
CCI Charlson Comorbidity Index
max maximum
SD standard deviation
ACEI Angiotensin Converting Enzyme Inhibitor
ARB Angiotensin Receptor Blocker
CCB Calcium Channel Blocker.
CI confidence interval
4 change
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